Management of AIDS-related Kaposi sarcoma: Advances in target discovery and treatment

AIDS Reader

Volumn 14, Issue 5, 2004, Pages 236-238+243

  Dezube, Bruce J ^a,b   Pantanowitz, Liron ^b   Aboulafia, David M ^c,d,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

^e Bailey Boushay House   (United States)

Author keywords

Cancer; HIV AIDS; Human herpesvirus; Kaposi sarcoma

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ALITRETINOIN; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTIRETROVIRUS AGENT; BLEOMYCIN; DAUNORUBICIN; DIDANOSINE; DOXORUBICIN; FUMAGILLIN; IMATINIB; INTERLEUKIN 12; PACLITAXEL; THALIDOMIDE; VINBLASTINE; VINCRISTINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; ANGIOGENESIS; ARTHRALGIA; BONE MARROW SUPPRESSION; CELL DIFFERENTIATION; CHILL; COGNITIVE DEFECT; FEVER; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LIVER TOXICITY; MYALGIA; NEUROPATHY; PATHOGENESIS; REMISSION; REVIEW; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASM STAGING; SARCOMA, KAPOSI; SKIN NEOPLASMS;

EID: 2442707861     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Martin JN, Osmond DH. Kaposi's sarcoma-associated herpesvirus and sexual transmission of cancer risk. Curr Opin Oncol. 1999;11:508-515.
2. Ensoli B, Barillari G, Salahuddin SZ, et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 1990;345:84-86.
3. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 1994;371:674-680.
4. Mesri EA. Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpes-virus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Blood. 1999;93:4031-4033.
5. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999;93:4034-4043.
6. Bais C, Geelen AV, Eroles P, et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell. 2003;3:131-143.
7. Pantanowitz L, Dezube BJ, Pinkus GS, Tahan SR. Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Cutan Pathol. 2004;31:26-34.
8. Dezube BJ. Acquired immunodeficiency syndrome-related Kaposi's sarcoma: clinical features, staging, and treatment. Semin Oncol. 2000;27:424-430.
9. Holland JC, Tross S. Psychosocial considerations in the therapy of epidemic Kaposi's sarcoma. Semin Oncol. 1987;14(2 suppl 3):48-53.
10. Nichols CM, Flaitz CM, Hicks MJ. Treating Kaposi's lesions in the HIV-infected patient. J Am Dent Assoc. 1993;124:78-84.
11. Danzig JB, Brandt LJ, Reinus JF, Klein RS. Gastrointestinal malignancy in patients with AIDS. Am J Gastroenterol. 1991;86:715-718.
12. Laine L, Amerian J, Rarick M, et al. The response of symptomatic gastrointestinal Kaposi's sarcoma to chemotherapy: a prospective evaluation using an endoscopic method of disease quantification. Am J Gastroenterol. 1990;85:959-961.
13. Aboulafia DM. The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma. Chest. 2000;117:1128-1145.
14. Huang L, Schnapp LM, Gruden JF, et al. Presentation of AIDS-related pulmonary Kaposi's sarcoma diagnosed by bronchoscopy. Am J Respir Crit Care Med. 1996;153:1385-1390.
15. Gruden JF, Huang L, Webb WR, et al. AIDS-related Kaposi sarcoma of the lung: radiographic findings and staging system with bronchoscopic correlation. Radiology. 1995;195:545-552.
16. Judson MA, Sahn SA. Endobronchial lesions in HIV-infected individuals. Chest. 1994;105:1314-1323.
17. Ioachim HL, Adsay V, Giancotti FR, et al. Kaposi's sarcoma of internal organs. A multiparameter study of 86 cases. Cancer. 1995;75:1376-1385.
18. Adal KA, Cockerell CJ, Petri WA Jr. Cat scratch disease, bacillary angiomatosis, and other infections due to Rochalimaea. N Engl J Med. 1994;330:1509-1515.
19. Gill PS, Loureiro C, Bernstein-Singer M, et al. Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1989;110:937-940.
20. Trattner A, Hodak E, David M, Sandbank M. The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer. 1993;72:1779-1783.
21. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989;7:1201-1207.
22. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15:3085-3092.
23. Nasti G, Talamini R, Antinori A, et al. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the HAART Erathe Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol. 2003;21:2876-2882.
24. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol. 2004;22:399-402.
25. Bower M, Fox P, Fife K, et al. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS. 1999;13:2105-2111.
26. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ. 1999;319:23-24.
27. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi's sarcoma. Nat Med. 2002;8:225-232.
28. Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood. 2002;99:3771-3779.
29. Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr. 1999;22:235-246.
30. Boudreaux AA, Smith LL, Cosby CD, et al. Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection. J Am Acad Dermatol. 1993;28:61-65.
31. Swift PS. The role of radiation therapy in the management of HIV-related Kaposi's sarcoma. Hematol Oncol Clin North Am. 1996;10:1069-1080.
32. Gressen EL, Rosenstock JG, Xie Y, Corn BW. Palliative treatment of epidemic Kaposi sarcoma of the feet. Am J Clin Oncol. 1999;22:286-290.
33. Lee FC, Mitsuyasu RT. Chemotherapy of AIDS-related Kaposi's sarcoma. Hematol Oncol Clin North Am. 1996;10:1051-1068.
34. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996;14:2353-2364.
35. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16:2445-2451.
36. Stewart S, Jablonowski H, Goebel FD, et al. Ranomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998;16:683-691.
37. Cooley HD, Volberding P, Martin F, et al. Final results of a phase III randomized trial of pegylated liposomal doxorubicin versus liposomal daunorubicin in patients with AIDS-related Kaposi's sarcoma. Proc Am Soc Clin Oncol. 2002;21:411a. Abstract 1640.
38. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol. 1999;17:1876-1883.
39. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol. 1998;16:1112-1121.
40. Krown SE, Li P, Von Roenn JH, et al. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS Clinical Trials Group study. J Interferon Cytokine Res. 2002;22:295-303.
41. Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. AIDS. 1999;13:283-284.
42. Nannan Panday VR, Hoetelmans RM, van Heeswijk RP, et al. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma-drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother Pharmacol. 1999;43:516-519.
43. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. J Clin Oncol. 1998;16:1444-1449.
44. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000;18:2593-2602.
45. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS Malignancy Consortium study. J Clin Oncol. 2002;20:153-159.
46. Pluda JM, Wyvill K, Little R. Administration of interleukin-12 to patients with AIDS-associated Kaposi's sarcoma: preliminary results of a pilot study. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;21:A29.
47. Koon H, Bubley G, Pantanowitz L, et al. AIDS-related Kaposi's sarcoma: imatinib mesylate-induced regression in c-kit positive disease. Presented at the 7th International Conference on Malignancies in AIDS and Other Immunodeficiencies; April 28-29, 2003; Bethesda, Md. Abstract 20.
48. Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis. 1996;173:1477-1480.